SEC Form 4 · accession 0001140361-19-001633
Opus Genetics, Inc. · IRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ely Benaim
Officer — Chief Medical Officer
Period of report
Jan 25, 2019
Accepted (ET)
Jan 25, 2019 · 7:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001228627
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.621 | Jan 25, 2019 | A | 100,000 | A | — | Jan 25, 2029 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1One quarter of the option vests and becomes exercisable on January 25, 2020, and, thereafter, 1/36th of the remaining option vests in equal installments on each monthly anniversary of such date until fully vested.